Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Praxis Precision Medicines, Inc.
PRAX
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.8B
$315.74
▼ -1.21%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$37.19 - $366.52
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 590.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Differentiated mechanism of action using extrasynaptic-preferring GABAA modulators with improved safety profiles
- Strategic partnerships with leading biotech companies (Ionis, Purdue) and research institutions providing scientific validation and development support
- Precision medicine approach targeting genetically-defined epilepsy populations with high unmet medical needs and potential for accelerated regulatory pathways
Bear Case
1 risk
- High volatility (beta 2.7). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Growing mid-cap in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+3.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 7, 2026
Reported EPS of -$3.20 vs -$3.58 consensus (+10.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+10.6%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
—
-100%
-100%
-100%
-100%
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$357.0K
$302.0K
$7.5M
$0
$0
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
13 analysts · 85% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
85%
Hold
8%
Sell
8%
Median Price Target
$595.50
▲ +88.6% vs $315.74
Latest: Needham · $575.00 · Jun 29, 2026
9 analysts covering